RNAi在非酒精性脂肪肝/NASH中的最新治疗作用。

3区生物学 Q2 Biochemistry, Genetics and Molecular Biology

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2023-12-29 DOI:10.1016/bs.pmbts.2023.12.005

Hamideh Dehghan, Alireza Ghasempour, Mahboobeh Sabeti Akbar-Abad, Zahra Khademi, Mahsa Sedighi, Tannaz Jamialahmadi, Amirhossein Sahebkar

{"title":"RNAi在非酒精性脂肪肝/NASH中的最新治疗作用。","authors":"Hamideh Dehghan, Alireza Ghasempour, Mahboobeh Sabeti Akbar-Abad, Zahra Khademi, Mahsa Sedighi, Tannaz Jamialahmadi, Amirhossein Sahebkar","doi":"10.1016/bs.pmbts.2023.12.005","DOIUrl":null,"url":null,"abstract":"Unhealthy lifestyles have given rise to a growing epidemic of metabolic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). NAFLD often occurs as a consequence of obesity, and currently, there is no FDA-approved drug for its treatment. However, therapeutic oligonucleotides, such as RNA interference (RNAi), represent a promising class of pharmacotherapy that can target previously untreatable conditions. The potential significance of RNAi in maintaining physiological homeostasis, understanding pathogenesis, and improving metabolic liver diseases, including NAFLD, is discussed in this article. We explore why NAFLD/NASH is an ideal target for therapeutic oligonucleotides and provide insights into the delivery platforms of RNAi and its therapeutic role in addressing NAFLD/NASH.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"204 ","pages":"45-67"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An update on the therapeutic role of RNAi in NAFLD/NASH.\",\"authors\":\"Hamideh Dehghan, Alireza Ghasempour, Mahboobeh Sabeti Akbar-Abad, Zahra Khademi, Mahsa Sedighi, Tannaz Jamialahmadi, Amirhossein Sahebkar\",\"doi\":\"10.1016/bs.pmbts.2023.12.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Unhealthy lifestyles have given rise to a growing epidemic of metabolic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). NAFLD often occurs as a consequence of obesity, and currently, there is no FDA-approved drug for its treatment. However, therapeutic oligonucleotides, such as RNA interference (RNAi), represent a promising class of pharmacotherapy that can target previously untreatable conditions. The potential significance of RNAi in maintaining physiological homeostasis, understanding pathogenesis, and improving metabolic liver diseases, including NAFLD, is discussed in this article. We explore why NAFLD/NASH is an ideal target for therapeutic oligonucleotides and provide insights into the delivery platforms of RNAi and its therapeutic role in addressing NAFLD/NASH.\",\"PeriodicalId\":21157,\"journal\":{\"name\":\"Progress in molecular biology and translational science\",\"volume\":\"204 \",\"pages\":\"45-67\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in molecular biology and translational science\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.pmbts.2023.12.005\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in molecular biology and translational science","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/bs.pmbts.2023.12.005","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

摘要

不健康的生活方式导致非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）等代谢性肝病日益流行。非酒精性脂肪肝通常是肥胖的结果，目前还没有美国食品及药物管理局批准的治疗药物。然而，治疗性寡核苷酸（如 RNA 干扰 (RNAi)）是一种很有前景的药物疗法，可以针对以前无法治疗的病症。本文讨论了RNAi在维持生理平衡、了解发病机制和改善包括非酒精性脂肪肝在内的代谢性肝病方面的潜在意义。我们探讨了为什么非酒精性脂肪肝/NASH 是治疗性寡核苷酸的理想靶点，并深入探讨了 RNAi 的传递平台及其在治疗非酒精性脂肪肝/NASH 中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

An update on the therapeutic role of RNAi in NAFLD/NASH.

Unhealthy lifestyles have given rise to a growing epidemic of metabolic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). NAFLD often occurs as a consequence of obesity, and currently, there is no FDA-approved drug for its treatment. However, therapeutic oligonucleotides, such as RNA interference (RNAi), represent a promising class of pharmacotherapy that can target previously untreatable conditions. The potential significance of RNAi in maintaining physiological homeostasis, understanding pathogenesis, and improving metabolic liver diseases, including NAFLD, is discussed in this article. We explore why NAFLD/NASH is an ideal target for therapeutic oligonucleotides and provide insights into the delivery platforms of RNAi and its therapeutic role in addressing NAFLD/NASH.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in molecular biology and translational science 生物-生化与分子生物学

CiteScore

6.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Progress in Molecular Biology and Translational Science (PMBTS) provides in-depth reviews on topics of exceptional scientiﬁc importance. If today you read an Article or Letter in　Nature　or a Research Article or Report in　Science　reporting ﬁndings of exceptional importance, you likely will ﬁnd comprehensive coverage of that research area in a future　PMBTS　volume.